logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produswest2
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produswest2
Yellow fever | Collections | MSF Science Portal

Collection Content

Journal Article
|
Commentary

Yellow fever resurgence: An avoidable crisis?

Lindsey NP, Horton J, Barrett ADT, Demanou M, Monath TP,  et al.
2022-11-02 • NPJ Vaccines
2022-11-02 • NPJ Vaccines
Journal Article
|
Research

Missed opportunities for vaccination (MOV) in children up to 5 years old in 19 Médecins Sans Frontières-supported health facilities: a cross-sectional survey in six low-resource countries

Borras-Bermejo B, Panunzi I, Bachy C, Gil-Cuesta J
2022-07-26 • BMJ Open
2022-07-26 • BMJ Open
OBJECTIVE
To describe missed opportunities for vaccination (MOV) among children visiting Médecins Sans Frontières (MSF)-supported facilities, their related factors, and to identify r...
Conference Material
|
Video

Immunogenicity of fractional dose yellow fever vaccine in children and HIV+ adults

Namulwana ML
2022-06-21 • Epicentre Scientific Day Paris 2022
2022-06-21 • Epicentre Scientific Day Paris 2022
Journal Article
|
Research

Metagenomic sequencing characterizes a wide diversity of viruses in field mosquito samples in Nigeria

Oguzie JU, Nwangwu UC, Oluniyi PE, Olumade TJ, George UE,  et al.
2022-05-10 • Scientific Reports
2022-05-10 • Scientific Reports
Mosquito vectors are a tremendous public health threat. One in six diseases worldwide is vector-borne transmitted mainly by mosquitoes. In the last couple of years, there have been activ...
Journal Article
|
Pre-Print

The burden of vaccine hesitancy for routine immunization in Yaounde-Cameroon: restrictive sampling technique

Yakum MN, Funwie AD, Ajong AB, Tsafack M, Ebaze LE,  et al.
2022-02-21 • medRxiv
2022-02-21 • medRxiv
Immunization is the most cost-effective health intervention in the world yet, vaccination uptake is still low with less than 50% of children aged 12-23 months fully vaccinated Cameroon. ...
Conference Material
|
Video

Fractional dosing of vaccines: when less could mean more

Juan A
2021-06-10 • Epicentre Scientific Day Paris 2021
2021-06-10 • Epicentre Scientific Day Paris 2021
Journal Article
|
Research

Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial

Juan-Giner A, Kimathi D, Grantz KH, Hamaluba M, Kazooba P,  et al.
2021-01-09 • Lancet
2021-01-09 • Lancet
BACKGROUND
Stocks of yellow fever vaccine are insufficient to cover exceptional demands for outbreak response. Fractional dosing has shown efficacy, but evidence is limited to the 17...
Journal Article
|
Research

Vaccination coverage survey versus administrative data in the assessment of mass yellow fever immunization in internally displaced persons—Liberia, 2004

Huhn GD, Brown J, Perea W, Berthe A, Otero H,  et al.
2006-02-06 • Vaccine
2006-02-06 • Vaccine
Yellow fever (YF) is a mosquito-borne vaccine-preventable disease with high mortality. In West Africa, low population immunity increases the risk of epidemic transmission. A cluster surv...
Journal Article
|
Letter

Shortage of vaccines during a yellow fever outbreak in Guinea

Nathan N, Barry M, Van Herp M, Zeller H
2001-12-01 • Lancet
2001-12-01 • Lancet
A yellow fever epidemic erupted in Guinea in September, 2000. From Sept 4, 2000, to Jan 7, 2001, 688 instances of the disease and 225 deaths were reported. The diagnosis was laboratory c...

See more collections

The endTB project

The endTB project

The endTB project aims to find shorter, less toxic and more effective treatments for ‘multidrug-resistant TB’ (MDR-TB) through:

  • access to new drugs
  • two clinical trials
  • advocacy at national and global levels

Covering 18 countries, the project is a partnership between Partners In Health, Médecins Sans Frontières, Interactive Research & Development and financial partners Unitaid and the Transformational Investment Capacity (TIC) of MSF. This collection contains the final and intermediate results of the studies, advocacy reports, and study presentations. For more information about the endTB project, visit https://endtb.org/.

MSF logo

Costs, cost-effectiveness, and financing of tuberculosis treatment

Tuberculosis (TB) is the world's deadliest infectious disease, and the leading killer of people with HIV. TB is curable, but it can be difficult to diagnose and tough to treat, especially for increasingly prevalent drug-resistant TB. In 2023, 22,700 people started TB treatment in MSF programs. Understanding the costs and cost-effectiveness associated with TB treatment and innovations, ranging from TB diagnostics and medications to TB care models, can help to plan resource needs and allocate resources effectively. Analyzing financing mechanisms can support developing sustainable funding models for TB control.

This collection spotlights articles by MSF and collaborators to analyze and document the costs of care, particularly diagnostics and medications.

MSF logo

World Malaria Day 2022
No description available
View All Collections
Yellow fever

Yellow fever